Q32 Bio (QTTB) Projected to Post Quarterly Earnings on Tuesday

Q32 Bio (NASDAQ:QTTB) is projected to post its Q4 2025 results before the market opens on Tuesday, March 10th. Analysts expect Q32 Bio to post earnings of ($1.06) per share for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, March 11, 2026 at 12:30 PM ET.

Q32 Bio Trading Up 3.5%

QTTB stock opened at $4.70 on Friday. The business’s 50-day moving average price is $3.98 and its two-hundred day moving average price is $3.00. The firm has a market cap of $57.81 million, a PE ratio of -1.37 and a beta of 0.14. Q32 Bio has a 1-year low of $1.35 and a 1-year high of $6.37.

Analyst Ratings Changes

QTTB has been the topic of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Q32 Bio in a research report on Friday, January 9th. HC Wainwright started coverage on Q32 Bio in a research report on Wednesday, February 25th. They issued a “buy” rating and a $13.00 price objective for the company. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $14.00.

Insiders Place Their Bets

In related news, CEO Jodie Pope Morrison sold 9,896 shares of the company’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $4.51, for a total value of $44,630.96. Following the completion of the transaction, the chief executive officer directly owned 89,104 shares of the company’s stock, valued at approximately $401,859.04. This represents a 10.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last three months, insiders have sold 16,706 shares of company stock valued at $75,344. 40.00% of the stock is currently owned by corporate insiders.

Institutional Trading of Q32 Bio

A number of institutional investors have recently modified their holdings of QTTB. Opaleye Management Inc. acquired a new position in shares of Q32 Bio during the fourth quarter worth about $708,000. Renaissance Technologies LLC raised its position in Q32 Bio by 110.6% in the 4th quarter. Renaissance Technologies LLC now owns 99,600 shares of the company’s stock valued at $331,000 after buying an additional 52,300 shares during the last quarter. Jane Street Group LLC bought a new stake in Q32 Bio in the 2nd quarter valued at approximately $69,000. AQR Capital Management LLC bought a new stake in Q32 Bio in the 1st quarter valued at approximately $68,000. Finally, Two Sigma Investments LP acquired a new position in Q32 Bio during the 3rd quarter worth approximately $62,000. 31.32% of the stock is currently owned by institutional investors.

Q32 Bio Company Profile

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.